Biography

Prof. Aron D. Mosnaim

Rosalind Franklin University of Medicine and Science, USA


Email: Aron.Mosnaim@rosalindfranklin.edu


Qualifications

1977 RPh., State of Illinois Pharmacy Board License 051-032662

1969 Ph.D., Strathclyde University, Glasgow, Great Britain, Organic Chemistry

1962 Pharm.D., University of Chile, Santiago, Chile

Publications (Selected)

  1. Litvak, J., Riesco, J., Atria, A., Lopez, O., Armedariz, R. and Mosnaim, A.D.: Diiodotyrosine metabolism in endemic goitri. Rev. Med. de Chile. 91:653-655, 1963.
  2. del Villar, E. and Mosnaim, A.D.:  Effect of DDT on incorporation of C14-labelled glucose into protein and soluble intermediates of nymphal triatoma infestans. Exp. Parasitology. 21:186-194, 1967.
  3. Mosnaim, A.D. and Nonhebel, D.C.: Reaction of cupric halides with organic compounds. II.9-Halogenoanthracenes. Tetrahedron. 25:1591-1595, 1969.
  4. Mosnaim, A.D., Nonhebel, D.C. and Russell, J.: Reaction of cupric halides with organic compounds, III. 9-Alkyl and 9-arylanythracenes. Tetrahedron. 25:3485-3492, 1969.
  5. Gibson, S., Mosnaim, A.D., Nonhebel, D.C. and Russell, J.: Reaction of cupric halides with organic compounds, V. Reactions of 9,10-dialkyl- and 9-alkyl-10-arylanthracenes. Tetrahedron.25:5047-5057, 1969.
  6. Mosnaim, A.D.: Ligand-Transfer reaction of cupric halides with organic compounds. Doctoral Thesis, Department of Pure and Applied Chemistry, Strathclyde University, Glasgow, Great Britain, 1969.
  7. Mosnaim, A.D.: Ligand-transfer reaction of cupric halides with organic compunds, National Lending Library, Walton Spa., Yorks, Great Britain, 1969.
  8. Mosnaim, A.D. and Nonhebel, D.C.: Reaction of cupric halides with organic compounds. VI. Reactions of 9-alkyl-and 9-aryl-10-halogenoanthracenes. J. Chem. Soc. (C):942-946, 1970.
  9. Mosnaim, A.D., Nonhebel, D.C. and Russell, J.: Reaction of cupric halides with organic compounds. VII. Reactions of 9-alkoxy- and 9-acyloxy-10-alkyl-anthracenes. Tetrahedron. 26: 1123-1129, 1970.
  10. Wolf, M.E. and Mosnaim, A.D.: Effect of temperature over alcaline phosphatase isoenzymes. Rev. Med. de Chile. 97(12):772-774, 1969.
  11. Flood, J., Mosnaim, A.D. and Nonhebel, D.C.: Bromination of some substituted 9-methylanthracenes. Chemical Communications. 12:761-762, 1970.
  12. Mosnaim, A.D., Wolf, M.E. and Nonhebel, D.C.: Gas-liquid and thin-layer chromatographic determination of some 9- and 9,10-substituted anthracenes. J. Chromatography. 70:154-157, 1972.
  13. Sabelli, H.C., Giardina, W.J., Mosnaim, A.D. and Sabelli, H.H.: A comparison of the functional roles of norepinephrine, dopamine, and phenylethylamine in the central nervous system. Acta Physiological Polonica. 24:33-40, 1973.
  14. Mosnaim, A.D. and Inwang, E.E.: A spectrophotometric method for quantification of 2-phenylethylamine in biological specimens. Analytical Biochemistry. 54:561-577, 1973.
  15. Mosnaim, A.D., Inwang, E.E., Sugerman, J.H., DeMartini, W.J. and Sabelli, H.C.:  Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its correlation with depression. Biological Psychiatry. 6(3):235-257, 1973.
  16. Inwang, E.E., Mosnaim, A.D. and Sabelli, H.C.: Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J. Neurochem. 20:1469-73, 1973.
  17. Mosnaim, A.D., Inwang, E.E., Sugerman, J.H. and Sabelli, H.C.: Identification of 2-phenylethamine in human urine by infrared and mass spectroscopy and its quantification in normal subjects and cardiovascular patients. Clinica Chimica Acta. 46:406-413, 1973.
  18. Mosnaim, A.D., Wolf, M.E., Saavedra, I., Amaro, A.M., Cordano, G. and Nonhebel, D.C.: Reaction of cupric (II) halides with organic compound. VIII. Pyrene and some 3-substituted pyrenes. Tetrahedron Letters. 17:1491-1494, 1973.
  19. Mosnaim, A.D., Wolf, M.E., Saavedra, I., Rosenkranz, A., Diaz, S. and Nonhebel, D.C.: Gas-liquid and thin-layer chromatographic determination of some 3- and 3,X-substituted pyrenes. J. Chromatography. 80:259-262, 1973.
  20. Inwang, E.E., Madubuike, U.P. and Mosnaim, A.D.: Evidence for the excretion of 2-phenylethylamine glucoronide in human urine. Experientia. 29(9):1080, 1973.
  21. Mosnaim, A.D., Sabelli, H.C. and Inwang, E.E.: The influence of psychotropic drugs on the levels of endogenous 2-phenylethylamine in rabbit brain. Biolog. Psychiatry. 8(2):227-234, 1974.
  22. Sabelli, H.C. and Mosnaim, A.D.: Phenylethylamine hypothesis of affective behavior. American Journal of Psychiatry. 131:695-699, 1974.
  23. Sabelli, H.C., Vazquez, A.J., Mosnaim, A.D. and Madrid-Pedemonte, L.: 2-Phenyle- thylamine as a possible mediator for 9-tetrahydrocannabinol-induced stimulation. Nature. 248:144-145, 1974.
  24. Sabelli, H.C., Pedemonte, W.A., Whalley, C., Mosnaim, A.D. and Vazquez, A.J.: Further evidence of a role of 2-phenylethylamine in the mode of action of 9-tetrahydrocannabinol. Life Sciences. 14:149-156, 1974.
  25. Borison, R.L., Mosnaim, A.D. and Sabelli, H.C.: Biosynthesis of brain 2-phenylethylamine: Influence of decarboxylase inhibition and D-amphetamine. Life Sciences. 15(10):1836-1848, 1974.
  26. Sabelli, H.C., Mosnaim, A.D. Vazquez, A.J., Madrid-Pedmonte, L.: (-)-Trans-tetrahydrocannabinol-induced increase in brain 2-phenylethylamine: Its possible role in the psychological effect of marihuana, in J.M. Singh and H. Lal (eds.): Drug Addiction/Volume 3: Neurobiology and Influences on Behavior. New York: Stratton 1974, pp. 271-284.
  27. Sabelli, H.C., Mosnaim, A.D. and Vazquez, A.J.:  Phenylethylamine: Possible role in depression and antidepressive drug action, in R.R. Drucker-Colin and R.D. Myers (eds.): Advances in Behavioral Biology/Volume 10: Neurohumoral Coding of Brain Function. New York: Plenum Publishing 1974, pp. 331-357.
  28. Borison, R.L. Mosnaim, A.D. and Sabelli, H.C.: Brain 2-phenylethylamine as a mediator for the central actions of amphetamine and methylphenidate. Life Sciences. 17:1331-1343, 1975.
  29. Sabelli, H.C., Mosnaim, A.D., Vazquez, A.J., Giardina, W.J., Borison, R.L. and Pedemonte, W.A.: Biochemical plasticity of synaptic transmission: A critical review of Dale's principle. Biological Psychiatry. 11:481-524, 1976.
  30. Borison, R.L., Mosnaim, A.D. and Sabelli, H.C.: Qualification of brain 2-phenylethylamine content by gas-liquid chromatography and its modification by marihuana. Clinical Research. 23: 550A, 1975.
  31. Silkaitis, R.P. and Mosnaim, A.D.: Pathways linking L-phenylalanine and 2-phenyl-ethylamine with p-tyramine in rabbit brain. Brain Research. 114:105-115, 1976.
  32. Pedemonte, W.A., Mosnaim, A.D. and Bulat, M.: Penetration of phenylacetic acid across the blood-cerebrospinal fluid barrier. Res. Comm. Chemical Pathol. Pharmacol. 14(1):111-116, 1976.
  33. Rubin, R., Patel, D., Singh, S. and Mosnaim, A.D.: Influence of hyperthyroidism on ethanol metabolism in rats. Clinical Research. 24:369A, 1976.
  34. Sabelli, H.C., Mosnaim, A.D., Borison, R.L. and Wolf, M.E.: Possible role of 2-phenylethylamine in the modulation of extrapyramidal function in B.N. Dhawan and P.B. Bradley (eds.): Drugs and Central Synaptic Transmission.  Baltimore: University Park Press, 1976, pp. 164-173.
  35. Zeller, E.A., Mosnaim, A.D., Borison, R.L. and Huprikar, S.V.: Phenylethylamine: Studies on the mechanism of its physiological action, in E. Costa, E. Giacobini and R. Paoletti (eds.): Advances in Biochemical Pharmacology/ Volume 15: First and Second Messengers-New Vistas. New York: Raven Press 1976, pp. 75-86.
  36. Ungar, F., Mosnaim, A., Ungar, B. and Wolf, M.E.: Tyramine binding by synaptosomes from rat brain: Effect of centrally active drugs. Biological Psychiatry. 12:661-668, 1977.
  37. Mosnaim, A.D., Edstrand, D.L., Wolf, M.E. and Silkaitis, R.P.: Evidence for an enzymatic p-tyramine-dehydroxylating system in rabbit brain preparations in vitro. Biochemical Pharmacology.26:1725-1728, 1977.
  38. Ungar, F., Mosnaim, A.D., Ungar, B. and Wolf, M.E.: Preliminary studies of the sodium borohydride stabilizable binding of phenylethylamine and tyramine to brain preparations. Res. Comm. Chemical Pathol. Pharmacol. 19:427-434, 1978.
  39. Mosnaim, A.D. and Wolf, M.E.:  Biochemical and pharmacological characterization of the phenylethylamine metabolic pathway, in A.D. Mosnaim and M.E. Wolf (eds.): Non-Catecholic Phenylethylamines Part 1: Phenylethylamine: Biological Mechanisms and Clinical Aspects. New York: Marcel Dekker, Inc. 1978, pp. 3-22.
  40. Mosnaim, A.D., Wolf, M.E., Huprikar, S., Singh, S.P. and Zeller, E.A.: Reduced monoamine oxidase activity in blood platelets from insulin-dependent diabetics. Diabetes. 28:455-456, 1979.
  41. Ungar, F., Ungar, B., Alivisatos, S., Mosnaim, A.D. and Wolf, M.D.: Non-enzymic interactions of nicotinamide adenine dinucleotide of some of its synthetic analogue and other compounds with orthophosphate.  Res. Comm. Chemical Pathol. Pharmacol. 25:395-398, 1979.
  42. Mosnaim, A.D., Silkaitis, R. and Wolf, M.E.: Rabbit brain metabolism of phenylethylamine and tyramine: Drug effects. Life Sciences. 27:557-566, 1980.
  43. Hansen, T.R., Greenberg, J. and Mosnaim, A.D.: Direct effect of phenylethylamine upon isolated vascular smooth muscle of the rat. Europ. J. Pharmacology. 63:95-101, 1980.
  44. Alcorn, W.C., Cromarty, F.M., Flood, J., Mancilla, J.M., Mosnaim, A.D., Nonhebel, D.C. and Scullion, I.: Reactions of copper (II) halides with aromatic compounds. Part XIII. The mechanisms of halogenation of some substituted 9-methylanthracenes. J. Chemical Research. 3:102-103, 1980.
  45. Mosnaim, A.D., Wolf, M.E., Callaghan, O. and Ungar, R.: Tyramine: metabolic and binding studies, in A.D. Mosnaim and M.E. Wolf (eds.): Non-catecholic Phenylethylamines Part 2: Phenylethanolamine, Tyramines and Octopamines. New York: Marcel Dekker, Inc. 201-229, 1980.
  46. Mosnaim, A.D., Callaghan, O.H. and Wolf, M.E.: Determination of non-catecholic phenylethylamines and monomethylated derivatives of phenylethylamines. J. Chromatography. Biomedical Applications 224:481-487, 1981.
  47. Wolf, M.D., Bowie, L., Keener, S., and Mosnaim, A.D.: Prolactin response in tardive dyskinesia. Biological Psychiatry. 17:485-490, 1982.
  48. Wolf, M.E., Ryan, J.J. and Mosnaim, A.D.: Organicity and tardive dyskinesia. Psychosomatics.23:475-480, 1982.
  49. Wolf, M.E., Almy, G., Toll, M. and Mosnaim, A.D.: Mania associated with the use of Baclofen. Biological Psychiatry. 17:757-759, 1982.
  50. Mosnaim, A.D., Karoum, F., Zeller, A., Callaghan, O.H., Singh, S.P. and Wolf, M.E.: Platelet monoamine oxidase activity and plasma levels of non-catecholic phenylethylamines in insulin-dependent diabetic subjects. Clinica Chimica Acta. 126:237-242, 1982.
  51. Mosnaim, A.D., Wine, R., Karoum, F., Diamond, S. and Wolf, M.E.: Methionine enkephalin, phenylethylamine, phenylacetic acid, platelet monoamine oxidase and prolactin in plasma of migraine patients. Clinical Pharmacology Therapeutics. 31(2): 251-252, 1982.
  52. Wolf, M.E. and Mosnaim, A.D.: Phenylethylamine in neuropsychiatric disorders. Gen. Pharmacology 14(4):385-390, 1983.
  53. Wolf, M.E., Keener, S., Mathis, P. and Mosnaim, A.D.: Phenylethylamine-like properties of Baclofen. Neuropsychobiology. 9:219-22, 1983.
  54. Wolf, M.E. Chevesich, J.E., Lehrer, E. and Mosnaim, A.D.: The clinical association of tardive dyskinesia and drug induced Parkinsonism. Biol. Psychiatry. 13(10):1181-1188, 1983.
  55. Mason, M., Wolf, M.E. and Mosnaim, A.D.: Studies on the mechanism of phenyle- thylamine uptake by rabbit erythrocytes. Compar. Biochem. Physiology. 76C:215-219, 1983.
  56. Wolf, M.E., Almy, G., Mathis, P. and Mosnaim, A.D.: Baclofen therapy in psychiatric patients. Clinical Pharmacology and Therapeutics. 33(2):244, 1983.
  57. Wolf, M., Ryan, J. and Mosnaim, A.D.: Cognitive functions in tardive dyskinesia. Psychological Medicine. 13(3):671-674, 1983.
  58. Wolf, M.E., Chevesich, J. and Mosnaim, A.D.: Trunkal tardive dyskinesia. Neurology. 33(4), Supp. 2:198, 1983.
  59. Karoum, F., Chuang, Lin-Whei, Mosnaim, A.D., Staub, R.A., and Wyatt, R.J.: Plasma and cerebrospinal fluid concentration of phenylacetic acid in humans and monkeys. J. Chrom. Sciences.21:546-550, 1983.
  60. Mosnaim A.D., Wolf, M.E. and Madubuike U.P.: Presence and biosynthesis of phenylacetic acid in the rabbit brain. Biochem. Pharmacology. 33(12):1993-1996, 1984.
  61. Wolf, M.E., Koller, W.C. and Mosnaim, A.D.: Electroencephalogram studies in tardive dyskinesia. Clinical Electroencephalography. 15(4):222-225, 1984.
  62. Wolf M.E. and Mosnaim A.D.: Tardive dyskinesia subtypes. Hospital Community Psychiatry.35(8):828-830, 1984.
  63. Mosnaim, A.D., Wolf, M.E., and Szanto, P.: Butaperazine effects on plasma methionine-enkephalin levels in patients with tardive dyskinesia. Res. Comm. Substance Abuse. 5(4):313-316, 1984.
  64. Mosnaim, A.D., Wine, R., Diamond, S. and Wolf, M.E.: Plasma methionine enkephalin levels during migraine episodes, in F.C. Rose (ed.): Progress in Migraine Research, Vol. 2. London, England: Pitman Book Ltd. 151-161, 1984.
  65. Paulos, M.A., Mosnaim, A.D., Wolf, M.E. and Tessel, R.E.: Phenylethylamine, phenylacetic acid and methionine enkephaline levels in humans following profound acute stress, in A. Boulton, G. Baker,W. Dewhurst and M. Sandler (eds.): Neurobiology of Trace Amines. New Jersey: Humana Press 563-569, 1984.
  66. Wolf, M.E. and Mosnaim, A.D.: Phenylethylamine and tardive dyskinesia, in A. Boulton, G. Baker, W. Dewhurst and M. Sandler (eds.): Neurobiology of Trace Amines. New Jersey: Humana Press 557-562, 1984.
  67. Callaghan, O., Mosnaim, A., Chevesich, J. and Wolf, M.: The kinetics of hydroxylation of phenylethylamine, amphetamine and phenylalanine in rodent tissues, in A. Boulton, G. Baker, W. Dewhurst and M. Sandler (eds.): Neurobiology of Trace Amines. New Jersey: Humana Press 307-312, 1984.
  68. Mosnaim, A.D., Wolf, M.E. and Diamond, S.: Non-catecholic phenylethylamines and  MAO activity in diabetes and migraine, in A. Boulton, G. Baker, W. Dewhurst and M. Sandler (eds.): Neurobiology of Trace Amines. New Jersey: Humana Press 549-566, 1984.
  69. Mosnaim, A.D., Wolf, ME. And Zeller, E.A.: Degradation kinetics by MAO of PEA derivatives. A model for the molecular basis of their analgesic and behavioral effects?, in A. Boulton, G. Baker, W. Dewhurst and M. Sandler (eds.): Neurobiology of Trace Amines. New Jersey: Humana Press 299-306, 1984.
  70. Wolf, M.E., Javaid, J.I., Mosnaim, A.D. and Davis, J.M.: Butaperazine kinetics in patients with tardive dyskinesia. Biopharmaceutics and Drug Disposition. 6:223-227, 1985.
  71. Mosnaim, A.D., Wolf, M.E., Chevesich, J., Callaghan, O.H. and Diamond, S.: Plasma methionine-enkephalin levels. A biological marker for migraine? Headache. 25(5):259-261, 1985.
  72. Wolf, M.E., De Wolfe, A., Ryan, J., Lips, O. and Mosnaim, A.D.: Vunerability to tardive dyskinesia. J. Clinical Psychiatry. 46:367-368, 1985.
  73. Wolf, M.E., Mosnaim, A.D., Owens, R., Paulos, M. and Hoffman, H.E.: Molindone pharmacokinetics in psychiatric patients. Res. Comm. Psychol. Psychiatry Behavior. 10(3):215-220, 1985.
  74. Mosnaim, A.D., Chevesich, J., Wolf, M.E., Freitag, D.O. and Diamond, S.: Plasma methionine-enkephalin. Increased levels during a migraine episode. Headache. 26(6):278-281, 1986.
  75. Wolf, M.E. and Mosnaim, A.D.: Lithium and molindone interactions: pharmacokinetic studies. Res. Comm. Psychol. Psychiatry Behavior. 11(1):23-28, 1986.
  76. Mosnaim, A.D., Wolf, M.E., Chevesich, J., Callaghan, O.H. and Szanto, P.: Phenylethylamine metabolism by postmortem human brain and liver preparations, in A. Boulton, et al., eds.: Neuropsychopharmacology of the trace Amines. New Jersey: Humana Press 487-498, 1986.
  77. Wolf, M.E., Mosnaim, A.D., Callaghan, O.H., Chevesich, J. and Caro, M.: Phenylethylamine metabolism to tyramine by postmortem human brain preparations. Life Sci. 40(5):489-494, 1987.
  78. Wolf, M.E., DeWolfe, A. and Mosnaim, A.D.: Risk factors for tardive dyskinesia according to primary psychiatric diagnostic. Hillside J. Clinical Psychiatry. 9(1):3-10, 1987.
  79. Mosnaim, A.D., Diamond, S., Freitag, F., Chevesich, J., Wolf, M.E. and Solomon, G.: Plasma and platelet methionine-enkephalin levels in chronic cluster patients during an acute headache episode. Headache. 27(6):325-328, 1987.
  80. Wolf, M.E., Alavi, A. and Mosnaim, A.D.: Pharmacological interventions in Vietnam Veterans with post traumatic stress disorder. Res. Comm. Psychol. Psychiatry Behavior. 12(3):169-176, 1987.
  81. Wolf, M.E., Alavi, A. and Mosnaim, A.D.: Aids related complex in a Vietnam Veteran with drug abuse. Res. Comm. Substance Abuse. 8:117-123, 1987.
  82. Diamond, S., Mosnaim, A.D., Freitag, F., Wolf, M.E., Lee, G. and Solomon, G.: Plasma methionine-enkephalin in patients with cluster headache, in F.C. Rose (ed.): Advances in Headache Research, Vol. 4, London: John Libbey & Co. Ltd. 4: 209-219, 1987.
  83. Wolf, M.E., Alavi, A. and Mosnaim, A.D.: Post traumatic stress disorder in Vietnam Veterans: Clinical-EEG findings; possible therapeutic effects of carbamazepine. Biological Psychiatry. 23:642-644, 1988.
  84. Mosnaim, A.D., Puente, J., Wolf, M.E., Callaghan, O.H., Busch, R. and Diamond, S.: Studies of the in vitro human plasma degradation of methionine-enkephalin. Gen. Pharmacology. 19(5):729-733, 1988.
  85. Wolf, M.E., Alavi, A. and Mosnaim, A.D.: Pain, dermatological and allergic conditions in post traumatic stress disorders. Res. Comm. Psychol. Psychiatry Behavior. 13(3):237-240, 1988.
  86. Mosnaim, A.D. and Wolf, M.E.: Administration of butaperazine and plasma methionine- enkephalin levels in schizophrenic and affective disorder patients with tardive dyskinesia. Journal Clinical Psychopharmacology. 8(4):Suppl. 275-315, 1988.
  87. Mosnaim, A.D., Callaghan, O.H. and Wolf, M.E.: Hydroxylation of phenylethylamine by rat liver preparations. Gen. Pharmacology. 19(5):729-733, 1989.
  88. Ayre, S., Skalestski, B. and Mosnaim, A.D.: Blood-brain barrier passage of azidothymidine in rats: effects of insulin. Res. Comm. Chemical Pathology Pharmacology. 63(1):45-52, 1989.
  89. Mosnaim, A.D., Diamond, S., Wolf, M.E., Puente, J. and Freitag, F.: Endogenous opioid-like peptides in headache. An overview. Headache. 29(6):368-372, 1989.
  90. Mosnaim, A.D., Wolf, M.E., Lee, G., Puente, J., Garmnerdsiri, S., Freitag, F. and Diamond, S.: Plasma degradation of methionine-enkephalin by cluster headache patients. In vitro studies. Headache Quarterly. Current Treatment and Research. 1(1):79-83, 1990.
  91. Mosnaim, A.D., Huprikar, S., Wolf, M.E. and Diamond, S.: Platelet monoamine oxidase in female migraine patients. Headache. 30(8):488-490, 1990.
  92. Wolf, M.E., Mosnaim, A.D., Puente, J. and Ignacio, R.: Methionine-enkephalin in post traumatic stress disorder. Plasma levels and degradation. Res. Comm. Psychology Psychiatry. Behavior 15(1-2):73-78, 1990.
  93. Wolf, M.E., Mosnaim, A.D., Ignacio, R. and Puente, J.:  Plasma methionine-enkephalin in post-traumatic stress disorder. Biological Psychiatry. 29:305-307, 1991.
  94. Maturana, P., Miranda, D., Sepulveda, C., Puente, J., Wolf, M.E., and Mosnaim, A.D.: Natural killer cell activity in patients with septic shock. J. Critical Care. 6:42-45, 1991.
  95. Wolf, M.E., Caro, M., and Mosnaim, A.D.: Lithium-neuroleptic interactions: Electroencephalographic studies. Res. Comm. Psychol. Psychiatry Behavior. 16(1-2):35-40, 1991.
  96. Mosnaim, A.D., Huprikar, S., Wolf, M.E., Freitag, F. and Diamond, S.: Studies of platelet monoamine oxidase activity during an acute cluster headache attack. Cephalalgia. 11(supp.11): 254-255, 1991.
  97. Wolf, M.E., de Wolfe, A.S. and Mosnaim, A.D.: The association of tardive dyskinesia with cognitive deficits. A review. Res. Comm. Psychol. Psychiatry Behavior. 16 (1-2):15-27, 1991.
  98. Mosnaim, A.D., Huprikar, S., Wolf, M.E., Freitag, F. and Diamond, S.: Studies of platelet monoamine oxidase activity in female migraineurs. An old story revisited, in F.C. Rose (ed.): New Advances in Headache Research: 2, London:  Smith-Gordon and Co. Ltd. 135-139, 1991.
  99. Puente, J., Maturana, P., Miranda, D., Navarro, C., Wolf, M.E. and Mosnaim, A.D.: Enhancement of human natural killer cell activity by opioid peptides: similar response to methionine-enkephalin and B-endorphin. Brain, Behavior Immunity. 6:32-39, 1992.
  100. Mosnaim, A.D., Huprikar, S., Wolf, M.E., Callaghan, O.H., Freitag, F. and Diamond, S.: Platelet monoamine oxidase activity in cluster headache patients. Headache Quarterly. Current Treatment and Research. III(2):172-176, 1992.
  101. Wolf, M.E., Mosnaim, G., Farinha, P. and Mosnaim, A.D.: Reinduction of neuroleptic malignant syndrome by lithium. Res. Comm. Psychol. Psychiatry Behavior. 17:69-72, 1992.
  102. Mosnaim, A.D.: Role of enkephalins and endorphins in headaches. In: Symposium "Neurobiologic Mechanisms as an Approach to the Pharmacology of Headache. (G. Solomon, ed.), Headache Quarterly. Current Treatment and Research. 3(3),309-318, 1992.
  103. Mosnaim, A.D.: Role of enkephalins in the regulation of pain in migraine and cluster headaches. National Headache Foundation Letter, pp.13, Summer 1992.
  104. Mosnaim, A.D., Wolf, M. E., Maturana, P., Mosnaim, G., Puente, J., Kucuk, O. and Gilman-Sachs, A.: In vitro natural killer cell activity in post traumatic stress disorder patients. Response to methionine-enkephalin challenge. Immunopharmacology. 25:107-116, 1993.
  105. Mosnaim, A.D., Wolf, M. E., Maturana, P., Puente, J., Freitag, F. and Diamond, S.: In vitro studies of natural killer cell activity in migraineurs. Changes in response to methionine-enkephalin challenge during an acute migraine episode. Headache Quarterly. Current Treatment and Research.4(1):36-41, 1993.
  106. Puente, J., Carvajal, T., Parra, S., Miranda, D., Sepulveda, C., Wolf, M.E. and Mosnaim, A.D.: In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2. International J. Clinical Pharmacology Therapeutics Toxicology.31(6):271-275, 1993.
  107. Wolf. M.E., Richer, S., Berk, M.A. and Mosnaim, A.D.: Cutaneous and ocular changes associated with the use of chlorpromazine. International J. Clinical Pharmacology Therapeutics Toxicology. 31(8):365-367, 1993.
  108. Mosnaim, A. D.: Symposium participant "New and Old Therapy for Vascular Headaches" (proceedings edited by Journal's staff). P&T (Pharmacy and Therapeutics. A Peer Reviewed Journal for Formulary Management). 18(6):575-582, 1993.
  109. Mosnaim, A.D.: Biochemical and immunological studies in migraine and cluster headaches. In: Symposium "New and Old Therapies of Vascular Headaches: Immune Approaches and Serotonin Receptors in Therapy". (A.D. Mosnaim proceedings ed). Headache Quarterly. Current Treatment and Research. 34-38: 1994.
  110. Puente, J., Carvajal, T., Parra, S., Miranda, D., Sepulveda, C., Wolf, M. E., and Mosnaim, A. D.: Enhancement of natural killer cell activity in septic shock patients by a mixture of the calcium ionophore A23187 and the phorbol ester TPA. In vitro studies. International J. Clinical Pharmacology Therapeutics Toxicology. 32(1):19-23, 1994.
  111. Wolf, M. E. and Mosnaim, A. D.: Improvement of axial dystonia with the administration of clozapine. International J. Clinical Pharmacology Therapeutics Toxicology. 32(6):282-283, 1994.
  112. Mosnaim, A. D., Wolf, M. E., Maturana, P., Puente, J., Freitag, F. and Diamond, S.: In vitro studies of natural killer cell activity in migraineurs. Changes in response to a B-endorphin challenge during an acute migraine episode. Headache Quarterly. Current Treatment and Research. 2:142-148, 1994.
  113. Mosnaim, A. D.: Biochemical and Immunological Studies in Migraine Headache. National Headache Foundation Newsletter, pp. 4-5, Winter 1994 (No. 87).
  114. Ranade, V.V., Wolf, M.E. and Mosnaim, A.D.: Generic drug industry: Current status and future prospects. Drug News & Perspectives. 197-204, 1994.
  115. Wolf, M.E. and Mosnaim, A.D.: Polypharmacy: a problem of the decade of the nineties. Drug News & Perspectives. 581-584, 1994.
  116. Ranade, V.V., Wolf, M.E. and Mosnaim, A.D.: Developments in antiarrhythmic drugs: An overview. Expert Opinion Investigational Drugs. 4(11):1-29, 1995.
  117. Puente, J., Diaz, M.A., Salas, M.A., Miranda, D., Gaggero, A., Wolf, M.E. and Mosnaim, A.D.: Studies of natural killer cell activity in a drug-free, healthy population. Response to a challenge with taxol, estramustine and lipopolysaccharide. International J. Clinical Pharmacolology Therapy.33(8):457-461, 1995.
  118. Mosnaim, A.D., Wolf, M.E., Curr, M., Mosnaim, J.M., Freitag, F. and Diamond, S.: Myths in migraine research: 1. Migraine and cluster headache patients are characterized by significant alterations in platelet monoamine oxidase activity. Headache Quarterly. Current Treatment and Research.7(3):225-234, 1996.
  119. Mosnaim, A.D., Freitag, F., Ignacio, R., Salas, M.A., Karoum, F., Wolf, M.E. and Diamond, S.: Apparent lack of correlation between tyramine and phenylethylamine content and the occurrence of food-precipitated migraine. Reexamination of a variety of food products frequently consumed in theUnited States and commonly restricted in tyramine-free diets. Headache Quarterly. Current Treatment and Research. 7(3):239-249, 1996.
  120. Puente, J., Salas, M.A., Cañon, C., Miranda, D., Wolf, M.E. and Mosnaim, A.D.: Activation of protein tyrosine kinase: a possible requirement for fixed-bacteria and lipopolysaccharide-induced increase in human natural killer cell. Int. J. Clinical Pharmacology Therapy. 34(5):212-218, 1996.
  121. Wolf, M.E., De Wolfe, A.S. and Mosnaim, A.D.: Cognitive deficits in tardive dyskinesia, in: R. Yassa, V. Nair and D. Jeste (eds.): Neuroleptic Induced Movement Disorders. Cambridge UniversityPress, United Kingdom 196-206, 1996.
  122. Sepúlveda, C., Puente, J., Weinstein, C., Wolf, M.E. and Mosnaim, A. D.: Enhancement of natural killer cell activity in HIV-1 infected subjects by a mixture of the calcium ionophore A23187 and the phorbol ester TPA. Lack of response to a similar challenge with interleukin-2 or alpha-interferon. American J. Therapeutics. 4(11-12):413-421, 1997.
  123. Karoum, F., Wolf, M.E. and Mosnaim, A.D.: Effects of the administration of amphetamine, either alone or in combination with reserpine or cocaine, on regional brain beta-phenylethylamine and dopamine release. American J. Therapeutics. 4(9-10):333-342, 1997.
  124. Mosnaim, A.D., Kulaga, H., Adams, J.A., Wolf, M.E., Freitag, F. and Diamond. S.: Flow cytometric analysis of lymphocyte subsets in migraine patients during and outside of an acute headache attack. Cephalalgia. 18(4):197-201, 1998.
  125. Wolf, M.E., Moffat, M., Ranade, V., Somberg, J.C., Lehrer, E. and Mosnaim, A.D.: Lithium, hypercalcemia and arrythmia. J. Clin. Psychopharmacology. (Peer reviewed Letter). 18:420-423, 1998.
  126. Miranda, D., Puente, J., Blanco, L., Wolf, M.E. and Mosnaim, A.D.: In vitro effect of bacterial lipopolysaccharide on the cytotoxicity of human natural killer cells. Res. Comm. Molecular Pathology Pharmacology. 100(1):3-14, 1998.
  127. Valenzuela, M. A., Cartier, L., Collados, L., Kettlun, A. M., Araya, F., Concha, C., Flores, L., Wolf, M. E. and Mosnaim, A. D.: Gelatinase activity of matrix metalloproteinases in the cerebrospinal fluid of various patient populations. Res. Comm. Chemical Pathology Pharmacology. 104(1):42-52,1999.
  128. Ranade, V., Molnar, J., Khokher, T., Agarwal, A., Mosnaim, A.D. and Somberg, J.: Effect of angiotensin-converting enzyme therapy on QT interval dispersion. American J. Therapeutics. 6:257-261, 1999.
  129. Wolf, M. E., Ranade, V., Molnar, J., Somberg, J. and Mosnaim, A. D.: Hypercalcemia, arrhythmia and mood stabilizers. J. Clin. Psychopharmacology. 20(2):260-264, 2000.
  130. Puente, J., Blanco, B., Montoya, M., Miranda, D., Contreras, I., Vinés E., Wolf, M.E. andMosnaim, A.D.: Effect of S. Typhi wild type and O-antigen mutants on human natural killer cell activity. Intern. J. Clin. Immunology. 355-364, 2000.
  131. Mosnaim, A. D., Wolf, M. E., Tao, D.N., Puente, J., Freitag, and Diamond, S.: Degradation kinetics of leucine-enkephalin by plasma samples from healthy controls and various patient populations. In vitro drug effects. American J. Therapeutics. 7:185-194, 2000.
  132. Puente, J., Blanco, L., Carrasco, C., Miranda, D., Wolf, M.E. and Mosnaim, A.D.: Effect of Salmonella-infected human monocytes on natural killer cell cytotoxicity. In vitro studies. International Immunopharmacology. 1:1285-1293, 2001.
  133. Miranda, D., Puente, J., Blanco, L., Jara, P., Wolf, M.E. and Mosnaim, A.D.: Human natural killer cell lysis of Salmonella typhi intracellularly-infected U 937 cells. Res. Commun. Molec. Pathol. Pharmacology . 111:3-12, 2002.
  134. Mosnaim, A.D.: Invited editorial. Cephalalgia 22(7): 614-615, 2002.
  135. Mosnaim, A. D., Puente, J., Saavedra, R., Diamond, S. and Wolf, M.: In vitro human plasma leucine-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. Pharmacology. Intern J Experim and Clin Pharmacology. 67(1):6-13, 2003.
  136. Miranda, D., Puente, J., Blanco, L., Jara, P., Wolf, M.E. and Mosnaim, A.D.: Lysis of Salmonella typhi intracellularly-infected U.937 cells by human natural killer cells. Effect of protein kinase inhibitors. American J. Therapeutics. 10:32-39, 2003.
  137. Kettlun, A.M., Collados, C., García, L., Cartier, L.A., Wolf, M.E., Mosnaim, A.D. and Valenzuela, M.A.: Matrix metalloproteinases profile in patients with Creuztfeldt-Jakob Disease. International Journal of Clinical Practice. 57(6):475-478, 2003.
  138. Mosnaim, A.D., Puente, J., Hoang, C., Ranade, V. and Wolf, M.E.: Inhibition of human plasma leucine-enkephalin aminopeptidase hydrolysis by various endogenous peptides and a select number of clinically used drugs. American J. of Therapeutics. 11:459-465, 2004.
  139. Valenzuela, M.A., Cartier, L.A., Mosnaim, A.D., Wolf, M.E., Ketllun, A.M., Collados, C. and Garcia, L.: Proteinases and Prion Diseases, in Proteases in the Brain (U. Lendeckel and N. Hooper, eds). Springer, USA, pp. 179-202, 2005.
  140. Mosnaim, A.D., Ranade, V.R., Wolf, M.E., Puente, J. and Valenzuela, M.A.: Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents. American J. Therapeutics. 13:261-273, 2006.
  141. Puente, J., Mosnaim, A.D. and Wolf, M.: Stress, Opioid Peptides and the Immune Response, in Stress, Cytokines and the Immune Response (N. P. Plotnikoff, R.E. Faith, A.J. Murgo and R.A. Good, eds). CRC Press, Taylor & Francis Group, New York, pp.125-142, 2006.
  142. Mosnaim, A.D., Nguyen, T.D., Tse, R, Puente, J., Couceyro, P. and Wolf, M.E.: In vitro methionine-enkephalin degradation kinetics by human brain preparations. Neurochemical Research. 33(1):81-86, 2008.
  143. Mosnaim, A.D., Nguyen, T.D., Puente, J. and Wolf,, M.E.: Degradation kinetics of methionine5-enkephalin by select brain areas from patients with chronic schizophrenia. American J. Therapeutics. 15(2):126-130, 2008.
  144. Puente, J., Jaque, M.P., Carrasco, C., Cruz, C., Valenzuela, M.A., Wolf, M.E. and Mosnaim A.D.: Triptan drugs, natural killer cell cytotoxicity and neutrophils pro-matrix metalloproteinase-9 secretion. Headache. 40(10): 1482-1489, 2008.
  145. Mosnaim, A.D., Saavedra, R. and Wolf, M.E.: Bacitracin-sensitive aminopeptidase(s) degradation of methionine-enkephalin by human brain putamen and hippocampus preparations. Inhibition by phenothiazine drugs. American J. Therapeutics. 16:512-516, 2009.
  146. Mosnaim, A.D., Abiola, R., Wolf, M.E. and Perlmuter, L.C.: Etiology and risk factors for developing orthostatic hypotension. American J. Therapeutics. 17(1):86-91, 2010.
  147. Mosnaim, A.D., Puente, J. and Wolf, M.E.: Biological correlates of migraine and cluster headaches: an overview of their potential use in diagnosis and treatment. Pragmatic and Observational Research. 1:25-32, 2010.
  148. Mosnaim, A.D., FuCheng, C. and Wolf, M.E.: Degradation kinetics of methionine-enkephalin by human cerebrospinal fluid. In vitro studies. American J. Therapeutics. 18:9-13, 2011.
  149. Perlmuter, L.C., Sarda, G., Casavant, V., O’Hara, K.,Hindes, M., Knott, PT. and Mosnaim, A.D.: A  review of orthostatic blood pressure regulation and its association with mood and cognition. Clinical Autonomic Research. 22(2):99-107, 2012.
  150. Mosnaim, A.D., Maturana, P, Puente, J. and Wolf, M.E.: Decreased plasma methionine-enkephalin levels in cluster headache patients. American J. Therapeutics.  19(3):174-179, 2012.
  151. Mosnaim, A.D., Callaghan, O.H., Hudzik, T. and Wolf, M.E.: Rat brain-uptake index for phenylethylamine and various monomethylated derivatives. Neurochemical Research 38(4):842-846, 2013. PMID: 23389662.
  152. Perlmuter, L.C, Sarda, G, Casavant, V. and Mosnaim A.D.: A review of the etiology, associated comorbidities, and treatment of orthostatic hypotension. American J. Therapeutics.20(3):279-291, 2013. PMID: 23656967.
  153. Mosnaim, A.D., Maturana, P., Callaghan, O.H. and Wolf, M.E.: Changes in plasma methionine-enkephalin levels associated with a cluster headache episode. American J. Therapeutics. 20(5):463-468, 2013. PMID: 23353772.
  154. Mosnaim, A.D., Hudzik, T. and Wolf, M.E.: Analgesic effects of β-phenylethylamine and various methylated derivatives in mice. Neurochem Res. 39(9):1675-80, 2014. DOI: 10.1007/s11064-014-1354-7.
  155. Mosnaim, A.D. and Wolf, M.E. (eds.): Non-catecholic Phenylethylamines. Part 1: Phenylethylamine: Biological Mechanisms and Clinical Aspects. Marcel Dekker, Inc., New York, 1978.
  156. Mosnaim, A.D. and Wolf, M.E. (eds.): Non-catecholic Phenylethylamines. Part 2: Phenylethanolamine, Tyramines and Octopamine. Marcel Dekker, Inc., New York, 1980.
  157. Wolf, M.E. and Mosnaim, A.D. (eds.): Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. American Psychiatric Press, Washington, DC 1988.
  158. Wolf, M.E. and Mosnaim, A.D. (eds.): Post Traumatic Stress Disorder:  Etiology, Phenomenology and Treatment. American Psychiatric Press, Washington, DC 1990.
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top